Jayastu Senapati: Check out our poster on display at ASH23

Jayastu Senapati, Assistant Professor at the Department of Leukemia at MD Anderson Cancer Center, shared on X/Twitter:

“Check out our poster on display today at the American Society of Hematology (ASH23).
-High-risk cytogenetics (HG-CTG) loses prognostic impact with inotuzumab ozogamicin (InO) and blinatumomab (Blina) added to frontline HyperCVAD chemotherapy in newly diagnosed patients with Philadelphia negative B-cell Acute Lymphoblastic Leukemia.
-Further analysis underway.”

Source: Jayastu Senapati/X